Site brasileiro onde você pode comprar qualidade e entrega http://farmaciabrasilrx.com/ cialis barato em todo o mundo.

Microsoft word - 0072-0364-2008.doc

OTC Pharmaceuticals in
the United States
www.datamonitor.com
Datamonitor USA
Datamonitor Europe
Datamonitor Germany
Datamonitor Asia Pacific
ABOUT DATAMONITOR
Datamonitor is a leading business information company specializing in industry Through its proprietary databases and wealth of expertise, Datamonitor provides clients with unbiased expert analysis and in depth forecasts for six industry sectors: Healthcare, Technology, Automotive, Energy, Consumer Markets, and Financial The company also advises clients on the impact that new technology and eCommerce will have on their businesses. Datamonitor maintains its headquarters in London, and regional offices in New York, Frankfurt, and Hong Kong. The company serves the world’s largest 5000 companies. Datamonitor's premium reports are based on primary research with industry panels and consumers. We gather information on market segmentation, market growth and pricing, competitors and products. Our experts then interpret this data to produce detailed forecasts and actionable recommendations, helping you create new business Our series of company, industry and country profiles complements our premium products, providing top-level information on 10,000 companies, 2,500 industries and 50 countries. While they do not contain the highly detailed breakdowns found in premium reports, profiles give you the most important qualitative and quantitative summary information you need - including predictions and forecasts. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Datamonitor (Published December 2009) EXECUTIVE SUMMARY
Market Value
The United States OTC pharmaceuticals market grew by 3.7% in 2008 to reach a Market Value Forecast
In 2013, the United States OTC pharmaceuticals market is forecast to have a value of $27.3 billion, an increase of 15.8% since 2008. Market Segmentation I
Sales of cough and cold preparations generated 23% of the United States OTC Market Segmentation II
The United States generated 23.8% of the global OTC pharmaceuticals market's Market Share
Johnson & Johnson accounts for 13.6% of the United States OTC pharmaceuticals Distribution
Pharmacies and drugstores form a leading distribution channel in the United States OTC pharmaceuticals market, accounting for 59.3% of the total value. Datamonitor (Published December 2009) TABLE OF CONTENTS
EXECUTIVE SUMMARY
CHAPTER 1
Market Overview
Market Definition
Research Highlights
Market Analysis
CHAPTER 2
Market Value
CHAPTER 3
Market Segmentation I
CHAPTER 4
Market Segmentation II
CHAPTER 5
Market Share
CHAPTER 6
Competitive Landscape
CHAPTER 7
Leading Companies
Johnson & Johnson
Pfizer Inc.
Schering-Plough Corporation
CHAPTER 8
Distribution 28
CHAPTER 9
Market Forecasts
Market Value Forecast
CHAPTER 10
Macroeconomic Indicators
Datamonitor (Published December 2009)
CHAPTER 11
Appendix 31
11.1 Methodology 31
11.2 Industry Associations
11.3 Related Datamonitor Research
Datamonitor (Published December 2009)
LIST OF TABLES
United States OTC Pharmaceuticals Market Value: $ billion, 2004-2008.9 United States OTC Pharmaceuticals Market Segmentation I: % Share, by Value, United States OTC Pharmaceuticals Market Segmentation II: % Share, by United States OTC Pharmaceuticals Market Share: % Share, by Value, 2008 .12 Key Financials: Johnson & Johnson .20 Key Facts: Schering-Plough Corporation .24 Key Financials: Schering-Plough Corporation.26 United States OTC Pharmaceuticals Distribution: % Share, by Value, 2008 .28 United States OTC Pharmaceuticals Market Value Forecast: $ billion, 2008- United States Size of Population (million) , 2004-2008 .30 United States GDP (Constant 2000 Prices, $ billion), 2004-2008 .30 Datamonitor (Published December 2009) CHAPTER 1
MARKET OVERVIEW
1.1 Market
Definition
The OTC pharmaceuticals market values consists of the total sales of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). Market’s values are calculated using retail selling price (RSP) and include any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant annual average exchange rates. For the purpose of this report the Americas comprise Argentina, Brazil, Canada, Chile, Colombia, Mexico, Venezuela, and the US. Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and The global figure comprises the Americas, Asia-Pacific and Europe. 1.2 Research
Highlights
The United States OTC pharmaceuticals market generated total revenues of $23.6 billion in 2008, representing a compound annual growth rate (CAGR) of 3.3% for the Sales of cough and cold preparations proved the most lucrative for the United States OTC pharmaceuticals market in 2008, generating total revenues of $5.4 billion, equivalent to 23% of the market's overall value. The performance of the market is forecast to decelerate, with an anticipated CAGR of 3% for the five-year period 2008-2013, which is expected to lead the market to a value of $27.3 billion by the end of 2013. Datamonitor (Published December 2009) 1.3 Market
Analysis
The United States OTC pharmaceuticals market grew at an unsteady rate for the period spanning 2004-2008. The rate of growth for this market is expected to decelerate in the forthcoming five years. The United States OTC pharmaceuticals market generated total revenues of $23.6 billion in 2008, representing a compound annual growth rate (CAGR) of 3.3% for the period spanning 2004-2008. In comparison, the European and Asia-Pacific markets grew with CAGRs of 3.1% and 4.9%, respectively, over the same period, to reach respective values of $38.9 billion and $26.8 billion in 2008. Sales of cough and cold preparations proved the most lucrative for the United States OTC pharmaceuticals market in 2008, generating total revenues of $5.4 billion, equivalent to 23% of the market's overall value. In comparison, sales of vitamins and minerals generated revenues of $3.4 billion in 2008, equating to 14.4% of the The performance of the market is forecast to decelerate, with an anticipated CAGR of 3% for the five-year period 2008-2013, which is expected to lead the market to a value of $27.3 billion by the end of 2013. Comparatively, the European and Asia- Pacific markets will grow with CAGRs of 2.8% and 4.6%, respectively, over the same period, to reach respective values of $44.6 billion and $33.5 billion in 2013. Datamonitor (Published December 2009) CHAPTER 2
MARKET VALUE
The United States OTC pharmaceuticals market grew by 3.7% in 2008 to reach a The compound annual growth rate of the market in the period 2004-2008 was 3.3%. United States OTC Pharmaceuticals Market Value: $ billion,
2004-2008
$ billion
$ billion
CAGR, 2004-2008:
D A T A M O N I T O R
Figure 1:
United States OTC Pharmaceuticals Market Value: $ billion,
2004-2008
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 3
MARKET SEGMENTATION I
Sales of cough and cold preparations generated 23% of the United States OTC Sales of vitamins and minerals generated 14.4% of the market's value. United States OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008

Category %
Other 39.10%

Total 100.0%

D A T A M O N I T O R
Figure 2:
United States OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 4
MARKET SEGMENTATION II
The United States generated 23.8% of the global OTC pharmaceuticals market's Europe accounts for a further 39.1% of the global market's value. United States OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008

Geography %
Europe 39.10%Asia-Pacific 27.00%United States
Total 100.0%

D A T A M O N I T O R
Figure 3:
United States OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 5
MARKET SHARE
Johnson & Johnson accounts for 13.6% of the United States OTC pharmaceuticals Wyeth generates a further 5.5% of the market's value. United States OTC Pharmaceuticals Market Share: % Share, by
Value, 2008

Company %
Other 76.00%

Total 100.0%

D A T A M O N I T O R
Figure 4:
United States OTC Pharmaceuticals Market Share: % Share, by
Value, 2008
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 6
COMPETITIVE LANDSCAPE
The OTC pharmaceuticals market will be analyzed taking manufacturers of OTC drugs as players. The key buyers will be taken as pharmacies, general stores and supermarkets, and manufacturers of active pharmaceutical ingredients (API) as the The US OTC pharmaceutical market is highly fragmented, with the top three players holding 24% of the total market by value. Local distributors have less buyer power than the large supermarkets, due to their smaller size. However, certain buyers integrate backwards in this market, which increases pressure on market players, thus increasing buyer power at the same time. Suppliers include manufacturers of active pharmaceutical ingredients (API), and are most often supplied to pharmaceutical companies under contractual arrangements, increasing switching costs and enhancing the power of suppliers. Market entry is made more difficult by the product development costs where a new drug is concerned, and by the need to obtain approval for products from the Prescription drugs are the main substitute, but the threat they pose is weak: they are often only used in situations where no adequate OTC remedy exists. Rivalry is strong, with increasing consolidation among the market players leading to bigger However, the market growth in the US OTC drugs market mitigates rivalry somewhat, The US market will be analyzed taking the distributors of drugs, including pharmacies, general stores and supermarkets, as buyers. The pharmacies and drugstores form the most important distribution channel for OTC drugs in this market. These distributors have less buyer power than the large supermarkets, due to their smaller size. Moreover, large pharmaceutical companies with recognized brands wield considerable power over smaller pharmacies and drug stores, thus reducing the Retailers often exert significant power in supply chains, however, consumer preference for wide availability of self-medication options forces buyers in this market However, OTC drugs are much more important to the business of a pharmacy than a supermarket and as a result buyers' switching costs can differ slightly in this market. Datamonitor (Published December 2009) Buyers tend to integrate backward in this market but this is not common. However, when such integration takes place, it increases pressure on market players, increasing buyer power at the same time. Overall buyer power is moderate. Suppliers to the OTC pharmaceutical market are mainly manufacturers of Active Pharmaceutical Ingredients (API). Market players require a wide range of specialized ingredients, which maintains supplier power. However many large pharmaceutical companies have operations in chemical manufacturing. For instance, Teva Pharmaceuticals manufactures a number of API Merck & Co also has its own chemicals division. Smaller pharmaceutical companies do not have the sufficient infrastructure to manufacture chemical ingredients themselves, as they lack expertise and therefore are often heavily reliant upon API Although some chemical manufacturers only supply to pharmaceutical companies, many also supply to numerous industries and develop chemicals for food ingredients, animal feed and ceramic material manufacturers, reducing their dependence on revenues gained from pharmaceutical supply. APIs are most often supplied to pharmaceutical companies under contractual arrangements, increasing switching costs and enhancing the power of suppliers. The OTC drugs market in the US involves a high level of specialization and expertise with high upfront investment costs, making the market difficult to enter. The main costs are incurred from extensive clinical trials. Some OTC manufacturers invest in new product development which involves high development costs from extensive clinical trials. Despite this, smaller firms are prevalent in the market and can still achieve efficiency through collaborations with larger firms which allows them to benefit from increased funds (in the form of collaborative revenues), creating more innovation and research opportunities. The most realistic entry method would be as a small generic drug firm; a much less costly business model than developing branded drugs. However, in countries such as the US for a medicine to be granted OTC status, it must have a wide safety margin All countries have regulatory bodies that approve drugs for use such as the Food and Drug Administration (FDA) in the US. There are opportunities for new companies in over-the-counter drugs with the strong growth of the market. Datamonitor (Published December 2009) This is being fostered by an ageing population and by a global trend toward self medication. In the pharmaceutical industry, product recalls can damage brand image and issues over the safety of drugs can impact end users decision to purchase OTC Even in this market where some products are highly important to the end user, customer preferences can have a strong pull-through on manufacturers. However, it is unusual for an OTC drug to be withdrawn from the market due to safety issues although there have been a few instances. For instance, in 2005, the FDA removed phenylpropanolamine, a decongestant, from over the counter sale due to a study that found the drug caused increased risk of Drugs often become over-the-counter by switching from a prescription drug which can increase consumer confidence in the product. Overall the threat of new entrants is Prescription drugs offer an obvious substitute to OTC pharmaceuticals, but these are normally suited to treating more serious ailments, and thus largely fail to encroach into the OTC market. Moreover most pharmaceutical companies produce both OTC and prescription drugs, which diminishes any threat from this particular substitute. Many consumers now use alternative medicines, like homeopathy but often in conjunction with conventional medicine, thereby making them less threatening, and Sustained use of alternative medicines instead of scientific preparations is often linked with adherence to an alternative lifestyle, philosophy or political belief system, Thus, while there is niche demand for such products, the majority of the populace is unlikely to view alternative medicines as a viable alternative to OTC pharmaceuticals. Overall the threat from substitutes is assessed as weak. The OTC pharmaceutical market is witnessing increasing consolidation leading to creation of bigger companies and more competition in the market. These firms have typically high fixed costs, as drug research and development requires continued investment. Exit barriers are fairly high as most companies that manufacture OTC drugs are focused on the pharmaceutical market and are similar to Datamonitor (Published December 2009) There are some personal care companies in operation, involved in the OTC drugs market or even in prescription pharmaceuticals, and the differentiation of products mean that exit barriers are lower. For example, Reckitt Benckiser owns the Nurofen and Strepsils brand after acquiring Boots Healthcare International and is also primarily involved in the production and distribution of household cleaning and personal care products. In this market, manufacturers can differentiate by demonstrating a drug that has a greater clinical benefit than another and also through a strong brand image. For example, Ibuprofen is a popular painkiller but Nurofen is the best known brand which has achieved strong sales. Sales growth has been sustained by innovation and extensions to the product, for example the production of Nurofen fast relief. The growth in this market mitigates rivalry somewhat. Overall, rivalry with respect to the OTC drugs market is moderate. Datamonitor (Published December 2009) CHAPTER 7
LEADING COMPANIES
7.1 Johnson
Key Facts: Johnson & Johnson
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, United States Website: www.jnj.com Financial Year-End: D A T A M O N I T O R
Johnson & Johnson (J&J) engages in the manufacture of health care products, and provides health care related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. It is a holding company and has over 250 operating companies that conduct business worldwide. The company operates predominantly through three segments: consumer, pharmaceuticals, and medical devices and diagnostics. J&J's consumer segment develops and markets products for baby care, skin care, oral care, wound care and women's health care. It also offers nutritional and over-the counter pharmaceutical products. These products are distributed to individual consumers, wholesalers or directly to independent and chain retail outlets. The company offers baby care products through the Johnson's baby line of products. The company markets the body wash and bath additives products under the brand name AVEENO. The body wash products include positively radiant, daily moisturizing body wash, advanced care body wash 10 OZ and skin relief body wash. Bath additives include daily moisturizing foaming bath, daily moisturizing body wash, stress relief The company markets deodorants under the brand name Bebe. It also offers the soaps under the brand name Purpose, Vendome and Ambi. Datamonitor (Published December 2009) The major brands offered by J&J in skin care include Aveeno, Clean & Clear, Johnson's adult, Neutrogena, RoC, Lubriderm, Beijing Dabao Cosmetics, and Vendome product lines. The Oral Care products are offered under the Listerine and Reach brand names. Major brands in the women’s health franchise are the Carefree Pantiliners and Stayfree sanitary protection products. The product lines of nutritional and over-the-counter include Splenda, No Calorie Sweetener; Tylenol acetaminophen products; Sudafed cold, flu and allergy products; Zyrtec allergy products; Motrin IB ibuprofen products; and Pepcid AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals. The pharmaceutical segment produces and markets products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals. The major brands marketed by the segment include Remicade (infliximab) for the treatment of Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; Topamax (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; and Procrit (Epoetinalfa, sold outside the US as Eprex), to stimulate red blood cell production. J&J also offers Risperdal oral (risperidone) for treatment of the symptoms of schizophrenia, bipolar mania and irritability, Risperdal Consta (risperidone), a longacting injectable, and Invega TM (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; Levaquin (levofloxacin) and Floxin (ofloxacin), both in the anti-infective field.Furthermore, the company offers Concerta (methylphenidate HCl) for the treatment of attention deficit hyperactivity disorder; Aciphex/Pariet, a proton pump inhibitor comarketed with Eisa; and Duragesic/Fentanyl Transdermal (fentanyl transdermal system, sold outside the US as Durogesic), a treatment for chronic pain The medical devices and diagnostics segment offers a wide range of products used principally in the professional fields of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. The products are distributed to wholesalers, hospitals and retailers. The segment offers Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon’s surgical care and women’s health products. It also offers Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vistakon’s disposable contact lenses. The distribution to the health care professional markets is undertaken both directly and through surgical Datamonitor (Published December 2009) The international business of J&J is conducted by subsidiaries located in 56 countries The research facilities of J&J are located in the US, Belgium, Brazil, Canada, China, France, Germany, India, Japan, the Netherlands, Singapore and the UK. The company and its subsidiaries operate 147 manufacturing facilities. Of these, 61 are located in the US, 35 in Europe, 16 in the Western Hemisphere (excluding the US) and 35 in Africa, Asia and Pacific. In the US, eight facilities are used by the consumer segment, 12 by the pharmaceutical segment and 41 by the medical devices and Key Metrics
J&J generated revenues of $63.7 billion in the financial year (FY) ended December 2008, an increase of 4.3% over 2007. The company's net income totaled $12.9 billion in FY2008, an increase of 22.4% over 2007. During FY2008, the pharmaceutical segment recorded revenues of $24.6 billion, a The medical devices and diagnostics segment recorded revenues of $23.1 billion, an The US, Johnson & Johnson's largest geographical market, accounted for 50.7% of the total revenues in FY2008. Revenues from the US reached $32.3 billion in 2008, a Datamonitor (Published December 2009) Key Financials: Johnson & Johnson
All in $ millions, except for employee numbers and margins D A T A M O N I T O R
Figure 5:
Revenues & Profitability: Johnson & Johnson
D A T A M O N I T O R
Datamonitor (Published December 2009) 7.2 Pfizer
Key Facts: Pfizer Inc.
235 East 42nd Street, New York City 10017, New York, United States Website: www.pfizer.com Financial Year-End: D A T A M O N I T O R
Pfizer is engaged in developing, manufacturing and marketing of prescription medicines for humans and animals. The company operates in more than 150 countries. Recently in October 2009, Pfizer completed the acquisition of Wyeth, a US- based research driven big pharma company, for $68 billion. The company operates through two business segments: pharmaceutical and animal health. It also generates revenues from several other businesses including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. As these businesses are small, they are grouped under 'corporate/other The pharmaceutical segment includes Pfizer's products for the treatment for cardiovascular and metabolic diseases; central nervous system disorders; arthritis and pain; infectious and respiratory diseases; urogenital conditions; cancer; eye disease; endocrine disorders; and allergies. The top products under this segment include Lipitor (treatment of elevated cholesterol in the bloodstream), Norvasc (treatment of hypertension and angina), Zoloft (anti-depressant for the treatment of depression, panic disorder, obsessive-compulsive disorder in adults and children), Celebrex (treatment of osteoarthritis, adult rheumatoid arthritis, acute pain and menstrual pain), Neurontin (epilepsy medicine), Zithromax (treatment of certain types of bronchitis and pneumonia, for sinusitis and for ear infection), Viagra (treatment of erectile dysfunction), Bextra (arthritis medicine) and Xalatan (glaucoma medicine used for the treatment of open-angle glaucoma and ocular hypertension). Datamonitor (Published December 2009) The animal health segment discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. The products which the company markets under this segment are parasiticides, anti-inflammatories, vaccines, antibiotics and related medicines. The principal products under this segment include Revolution (parasiticide for companion animals), Rimadyl (relieves pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery), and Clavamox/Synulox (antibiotic for skin and soft tissue infections in dogs and cats). The company's vaccine portfolio for livestock includes RespiSureOne/ StellamuneOne (single-dose vaccine used to prevent pneumonia in swine), and Bovi- Shield Gold (cattle vaccine for reproductive and respiratory protection). With the acquisition of Wyeth, Pfizer now offers over-the-counter (OTC) drugs that address a variety of health needs, such as muscle and body aches, allergies, colds and coughs, and nutritional supplements. The key OTC brands include Advil, Alavert, Anbesol, Caltrate, Centrum, Chapstick, Dimetapp, Preparation H, Robitussin and Though Pfizer's global manufacturing division is based in the US, the company operates plants in about 46 locations around the world. The company's major facilities are located in Belgium, France, Germany, Ireland, Italy, Japan, Puerto Rico, Key Metrics
Pfizer recorded revenues of $48.3 billion during the financial year (FY) ended December 2008, a decrease of 0.3% over FY2007. The net income totaled $8.1 billion in FY2008, a decrease of 0.5% over FY2007. The US, Pfizer's largest geographic market, accounted for 42.3% of the total revenues in FY2008. Revenues from the US reached $20.4 billion in 2008, a Key Financials: Pfizer Inc.
All in $ millions, except for employee numbers and margins D A T A M O N I T O R
Datamonitor (Published December 2009) Figure 6:
Revenues & Profitability: Pfizer Inc.
s
n
40,000
D A T A M O N I T O R
Datamonitor (Published December 2009) 7.3 Schering-Plough
Corporation
Key Facts: Schering-Plough Corporation
2000 Galloping Hill Road, Kenilworth, New Jersey 07033 0530, United States Website: www.schering-plough.com Financial Year-End: D A T A M O N I T O R
Schering-Plough Corporation (Schering-Plough) engages in the discovery, development, manufacturing and marketing of medical therapies and treatments. The company also manufactures consumer and animal health products. Schering-Plough has subsidiaries in more than 55 countries outside of the US. The company primarily operates in the US, Europe and Canada. It is headquartered in Kenilworth, New Schering-Plough operates through three segments: prescription pharmaceuticals, consumer health care, and animal health. The prescription pharmaceutical segment discovers, develops, manufactures and markets human pharmaceutical products. The segment undertakes research projects and markets products in the following six therapeutic areas: cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and For cardiovascular disease, the company offers Vytorin, a cholesterol-lowering tablet; and Zetia, a novel cholesterol-absorption inhibitor. It also offers Integrilin Injection, a platelet receptor GP IIb/IIIa inhibitor for the treatment of patients with acute coronary syndrome and those undergoing percutaneous coronary intervention in the US, as well as for the prevention of early myocardial infarction in patients with acute coronary syndrome in most countries. Schering-Plough also offers Orgaran, a non-heparin Datamonitor (Published December 2009) For the central nervous system, Schering-Plough offers Remeron, an antidepressant; Esmeron/Zemuron, a muscle relaxant used in surgical procedures; and Subutex, a sublingual tablet formulation of buprenorphine. The company also offers Suboxone, a sublingual tablet combination of buprenorphine and naloxone, in certain countries outside the US for the treatment of opiate addiction. Furthermore, it offers Norcuron, a muscle relaxant and Bridion (sugammadex), an anesthesia reversal agent. For immunology and infectious disease, Schering-Plough offers Remicade, an anti- TNF antibody outside of the US, Japan and certain Asian markets for the treatment of inflammatory diseases; and Pegintron Powder for Injection, a pegylated interferon product for chronic hepatitis C. It also offers Rebetol Capsules for use in combination with Pegintron or Intron A for treating hepatitis C; Avelox, which Schering-Plough only markets in the US, a broad-spectrum fluoroquinolone antibiotic for certain respiratory and skin infections; and Noxafil Oral Suspension, for prophylaxis (prevention) of invasive fungal infections in high-risk patients and the treatment of oropharyngeal For oncology, the company offers Temodar/Temodal for certain types of brain tumors; Caelyx, a long-circulating pegylated liposomal formulation of the cancer drug doxorubicin; and Intron A injection, marketed for chronic hepatitis B and C and numerous anticancer indications worldwide, including as adjuvant therapy for For respiratory problems, Schering-Plough offers Nasonex, a nasal-inhaled steroid for nasal allergy symptoms; and Clarinex/Aerius/Claritin Rx, a non-sedating antihistamine for the treatment of allergic rhinitis. It also offers Foradil Aerolizer, a long-acting beta2-agonist marketed by Schering-Plough in the US for the maintenance treatment of asthma and chronic obstructive pulmonary disease, and for the acute revention of exercise-induced bronchospasm. Furthermore, the company also offers Asmanex Twisthaler, an oral dry-powder corticosteroid inhaler for first-line maintenance treatment of asthma; and Proventil HFA (albuterol) inhalation aerosol. Schering-Plough offers a number of products for women’s health. They include Follistim/Puregon, a fertility treatment; Livial, a menopausal therapy; Marvelon/Desogen, a low-dose combined oral contraceptive. The company also offers Mercilon, a low-dose combined oral contraceptive; Cerazette, a progestin only oral contraceptive; and Implanon, a single-rod subdermal contraceptive implant. The animal health segment discovers, develops, manufactures and markets animal health products, including vaccines. The products marketed by the segment include livestock products, poultry products, companion animal products and aquaculture Datamonitor (Published December 2009) The consumer health care segment develops, manufactures and markets over-the- counter (OTC), foot care and sun care products. The OTC products offered comprise Claritin non-sedating antihistamines; Miralax treatment for occasional constipation; Coricidin HBP decongestant-free cold/flu medicine for people with high blood pressure; Afrin nasal decongestant spray; and Correctol laxative tablets. The foot care product line consists of DR. Scholl’s foot care products; Lotrimin topical antifungal products; and Tinactin topical antifungal products and foot and sneaker The suncare products offered consist of Coppertone sun care lotions, sprays, dry oils and lip-protection products and sunless tanning products. It also includes Solarcaine The company operates in Canada through Schering-Plough Canada. It offers a variety of sun care products under the Coppertone brand. The product line comprises general protection products, special skin care products, products for babies and kids, products for sports/active living, continuous spray products, and sunless and after- sun products. Schering-Plough Canada also offers sunburn relief products under the Key Metrics
Schering-Plough generated revenues of $18.5 billion in the financial year (FY) ended December 2008, an increase of 45.8% over 2007. The company's net income totaled $1.9 billion in FY2008, as compared to a net loss of $1.5 billion in 2007. The consumer health care segment recorded revenues of $1.3 billion in FY2008, an The US accounted for 30% of the total revenues in FY2008. Revenues from the US reached $5.6 billion in 2008, an increase of 20.9% over 2007. Table 10:
Key Financials: Schering-Plough Corporation
All in $ millions, except for employee numbers and margins D A T A M O N I T O R
Datamonitor (Published December 2009) Figure 7:
Revenues & Profitability: Schering-Plough Corporation
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 8
DISTRIBUTION
Pharmacies and drugstores form a leading distribution channel in the United States OTC pharmaceuticals market, accounting for 59.3% of the total value. Supermarkets and hypermarkets account for a further 34.9% of the market's value. Table 11:
United States OTC Pharmaceuticals Distribution: % Share, by
Value, 2008

Channel %
Other 2.50%

Total 100.0%

D A T A M O N I T O R
Figure 8:
United States OTC Pharmaceuticals Distribution: % Share, by
Value, 2008
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 9
MARKET FORECASTS
Market Value Forecast
In 2013, the United States OTC pharmaceuticals market is forecast to have a value of $27.3 billion, an increase of 15.8% since 2008. The compound annual growth rate of the market in the period 2008-2013 is predicted Table 12:
United States OTC Pharmaceuticals Market Value Forecast: $
billion, 2008-2013
$ billion
$ billion
CAGR, 2008-2013:
D A T A M O N I T O R
Figure 9:
United States OTC Pharmaceuticals Market Value Forecast: $
billion, 2008-2013
D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 10 MACROECONOMIC INDICATORS
Table 13:
United States Size of Population (million) , 2004-2008

Year Population
(million)
D A T A M O N I T O R
Table 14:
United States GDP (Constant 2000 Prices, $ billion), 2004-2008
Constant 2000
Prices, $ billion
D A T A M O N I T O R
Table 15:
United States Inflation, 2004-2008

Year Inflation
2004 2.72005 3.42006 3.22007 2.82008 4.3 D A T A M O N I T O R
Datamonitor (Published December 2009) CHAPTER 11
APPENDIX
11.1 Methodology
Datamonitor Industry Profiles draw on extensive primary and secondary research, all aggregated, analyzed, and cross-checked and presented in a consistent and Review of in-house databases – Created using 250,000+ industry interviews and
consumer surveys and supported by analysis from industry experts using highly complex modeling & forecasting tools, Datamonitor’s in-house databases provide the foundation for all related industry profiles Preparatory research – We also maintain extensive in-house databases of news,
analyst commentary, company profiles and macroeconomic & demographic information, which enable our researchers to build an accurate market overview Definitions – Market definitions are standardized to allow comparison from country to
country. The parameters of each definition are carefully reviewed at the start of the research process to ensure they match the requirements of both the market and our Extensive secondary research activities ensure we are always fully up-to-date with
Datamonitor aggregates and analyzes a number of secondary information sources, National and International trade associations Business information libraries and databases Modeling & forecasting tools – Datamonitor has developed powerful tools that
allow quantitative and qualitative data to be combined with related macroeconomic and demographic drivers to create market models and forecasts, which can then be refined according to specific competitive, regulatory and demand-related factors Continuous quality control ensures that our processes and profiles remain focused,
Datamonitor (Published December 2009) 11.2 Industry
Associations
Consumer Healthcare Products Association
900 19th Street, NW, Suite 700, Washington, DC 20006, USA
Tel: 1 202 429 9260
Fax: 1 202 429 9260
http://www.chpa-info.org
11.3 Related Datamonitor Research
Datamonitor Industry Profiles
OTC Pharmaceuticals in the United Kingdom Datamonitor (Published December 2009) Copyright of OTC Pharmaceuticals Industry Profile: United States is the property of Datamonitor Plc and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Source: http://campus.udayton.edu/~jrs/bai151/docs/industries/Industry%20report%20on%20US%20OTC%20pharmaceuticals.pdf

anbos.nl

Exameneisen Inleiding Voor u liggen de exameneisen voor de specialisatie Acne. Deze eisen zijn opgesteld door ISEO Consult in samenwerking met het KWC, op basis van het commentaar van drie deskundigen uit het vak, te weten: de dames K. Lubkemann, C. Oosterwijk en C.Prent. De exameneisen zijn ter vaststelling voorgelegd aan het bestuur van ANBOS. De vaststellingsdatum vindt u op het voor

Invitation biopartnering north america 2011 for life science nord

An die Cluster-Mitglieder Life Science Nord Sehr geehrte Damen und Herren, ich möchte Sie gerne auf die BioPartnering North America™ vom 27. Februar bis 1. März im kanadischen Vancouver hinweisen. Als die führende Biotechnologie Partnering-Konferenz in Kanada wurde die BioPartnering North America™ im letzten Jahr von über 800 Branchenvertretern aus über 26 Ländern bes

Copyright © 2010-2014 Articles Finder